Posted in | News | Business | Materials Analysis

Phasefocus Appoints New Board Members

Phase Focus Ltd (Phasefocus), the company that is revolutionising microscopy and imaging with the lens-free Phasefocus Virtual Lens® technology, today announced changes to its board of directors.

Paul Atherton, a successful serial technology entrepreneur, has been appointed Chairman of the Board. Paul co-founded Queensgate Instruments and was Managing Director from 1988 until its sale for more than £200 million in March 2000. Paul is also Chairman of Infinitesima, NanoVentures and Nexeon, and was Chairman of C2V and Midaz Lasers until their respective acquisitions by Thermo-Fisher in 2009 and Coherent in 2012. Paul is a board member of Imperial Innovations Group plc and was involved in its £200 million AIM flotation. He earned a PhD in Physics from Imperial College and an MBA from the London Business School (of which he was a Governor for six years) and has extensive expertise in photonics, electronics, mechanics and nanotechnology.

Paul said, "I am delighted to be taking on this role. Phasefocus has already made some excellent progress and I am very much looking forward to working with the team to build on these achievements."

Charles Holroyd has also been appointed as non-executive director. For the last three years Charles has been Group Business Development Director of Oxford Instruments, a £350 million-turnover, London Stock Exchange-listed manufacturer of high technology instrumentation, with responsibility for (among other things) acquisitions, divestments and joint ventures. Previously, Charles was Managing Director of the Oxford Instruments Analytical business unit, as well as being responsible for Oxford Instruments' commercial activities and brand development in Brazil, Russia, India and China.

Martin Humphry has been appointed director and Chief Technology Officer. An inventor on a number of Phasefocus' patent applications, Martin has assumed successively higher levels of responsibility since he joined the Company in 2009, including oversight of all of its product development and R&D activities.

After five years of service with the Company, Neil Loxley will be resigning as non-executive director, due to his recent appointment as CEO of Ibex Innovations, a developer of advanced X-ray detectors.

David Baynes, CEO of Fusion IP plc and Phasefocus' outgoing Chairman, will remain a non-executive director. Commenting on the appointments, David said, "I am delighted to welcome Paul, Charles and Martin to the board. Together, these new directors will bring a wealth of technical, marketing, operational and strategic experience to our board, which will be most welcome and valuable at this important juncture in the Company's history."

Ian Pykett, CEO of Phasefocus, said, "Paul and Charles bring tremendous experience in highly relevant markets, and in growing and realising value from venture capital-backed high-technology businesses. That we have been successful in attracting their world-class skills and experiences is testament not only to the success that we have achieved to date, but also to the vision that they share with us of a potentially very bright future for Phasefocus.

"I am equally pleased that we will continue to benefit not only from Martin's considerable technical knowledge, but also from the strategic insights and business development instincts that he brings to the board.

"We will very much miss Neil, who has for four years provided expert guidance and advice gained from his extensive prior experience in the high-technology instrumentation market. We wish him well at Ibex."

To find out about the company and to learn more about using Phasefocus' unique lens-less solutions for electron microscopy, label-free live cell cycle analysis and metrology, visit the Phasefocus website.

About Phasefocus

Phasefocus is a venture capital-backed spin-out company from the University of Sheffield founded in 2006. Its principal equity investors are Ombu Group and Fusion IP plc. In February 2013, the Company announced that it had entered into a Licencing Agreement with Gatan Inc., the world's leading manufacturer of instrumentation and software used to enhance and extend the operation and performance of electron microscopes.

A prototype "add-on" product for existing electron microscopes has already demonstrated an improvement in resolution of a factor of five over that available using the host instrument's conventional electron optics.

Its products also include an optical microscope used for label-free time-lapse imaging of biological cells, and an Ophthalmic Lens Profiler that can measure soft contact lenses with unprecedented levels of resolution and accuracy.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Phasefocus. (2019, February 08). Phasefocus Appoints New Board Members. AZoM. Retrieved on May 14, 2024 from https://www.azom.com/news.aspx?newsID=38986.

  • MLA

    Phasefocus. "Phasefocus Appoints New Board Members". AZoM. 14 May 2024. <https://www.azom.com/news.aspx?newsID=38986>.

  • Chicago

    Phasefocus. "Phasefocus Appoints New Board Members". AZoM. https://www.azom.com/news.aspx?newsID=38986. (accessed May 14, 2024).

  • Harvard

    Phasefocus. 2019. Phasefocus Appoints New Board Members. AZoM, viewed 14 May 2024, https://www.azom.com/news.aspx?newsID=38986.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.